Safety evaluations were performed on all patients exposed to at least one dose of aflibercept (safety-evaluable population).
Safety evaluations included: adverse events, vital signs, physical examination, clinical laboratory evaluations and electrocardiograms.
Safety evaluations were based on self-report of symptoms (or of adverse effects), various examinations, and laboratory tests.
Safety evaluations included safety and tolerability assessments, adverse events, pupil size and electronystagmography, and subjective dissociative effects measured by the 27-item Clinician Administered Dissociative States Scale (CADSS).
Safety evaluations included adverse events (AEs) and routine laboratory analyses.
Safety evaluations included the measurement of vital signs and assessment for adverse events on day 1.
Safety evaluations, measurement of BCVA, eye examinations, and OCT scans were conducted at all study visits.
Safety evaluations included physical examinations, electrocardiogram, standard laboratory tests and measurement of vital signs.
Safety evaluations included adverse events (AEs) and the unified Parkinson disease rating scale.
Safety evaluations included recording of AEs, laboratory values, dose interruptions/adjustments, and study drug discontinuations.
Safety evaluations included adverse event (AE) monitoring, physical examinations, and C SSRS [ 15].
